scholarly journals Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia

Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1854-1861 ◽  
Author(s):  
Eduard J. Libourel ◽  
Clara P. W. Klerk ◽  
Yvette van Norden ◽  
Moniek P. M. de Maat ◽  
Marieke J. Kruip ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Disseminated Intravascular Coagulation ◽  
Arterial Thrombosis ◽  
Myeloid Leukemia ◽  
Strong Predictor ◽  
Newly Diagnosed ◽  
Intravascular Coagulation ◽  
Key Points ◽  
D Dimer ◽  
Acute Myeloid

Key Points A high D-dimer level strongly predicts symptomatic venous and arterial thrombosis in newly diagnosed AML. Thrombosis occurs in up to 10% of patients with newly diagnosed AML.

scholarly journals Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

2018 ◽  
Vol 2 (11) ◽  
pp. 1277-1282 ◽  
Author(s):  
Vijaya Raj Bhatt ◽  
Valerie Shostrom ◽  
Krishna Gundabolu ◽  
James O. Armitage
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
The United States ◽  
Insurance Status ◽  
Newly Diagnosed ◽  
Key Points ◽  
Facility Type ◽  
Acute Myeloid

Key Points An analysis of 61 775 adults with AML diagnosed between 2003 and 2011 demonstrated that 25% did not receive any chemotherapy. Factors such as facility type, patients’ race, income, and insurance status were associated with the rates of use of chemotherapy.

scholarly journals Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Blood ◽  
2013 ◽  
Vol 121 (13) ◽  
pp. 2424-2431 ◽  
Author(s):  
Roland B. Walter ◽  
Megan Othus ◽  
Alan K. Burnett ◽  
Bob Löwenberg ◽  
Hagop M. Kantarjian ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Who Classification ◽  
Newly Diagnosed ◽  
Prognostic Information ◽  
Classification Analysis ◽  
Key Points ◽  
Acute Myeloid

Key Points The FAB type (ie, M0-M7) does not provide prognostic information for cases of “AML, NOS” in the 2008 WHO classification.

scholarly journals GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Blood ◽  
2019 ◽  
Vol 134 (12) ◽  
pp. 935-945 ◽  
Author(s):  
Adriano Venditti ◽  
Alfonso Piciocchi ◽  
Anna Candoni ◽  
Lorella Melillo ◽  
Valeria Calafiore ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Newly Diagnosed ◽  
Allogeneic Stem Cell Transplant ◽  
Younger Adults ◽  
Key Points ◽  
Acute Myeloid

Key Points A risk-adapted, MRD-driven transplant strategy is a feasible approach for the treatment of younger adults with AML. Pretransplant MRD positivity should not contraindicate delivery of an allogeneic stem cell transplant.

Sign in / Sign up

Export Citation Format

Share Document